白蛋白结合型紫杉醇联合贝伐珠单抗治疗复发性卵巢癌的临床分析_陈杰.pdf

2016 04 24 07 MODEＲN ONCOLOGY ，Apr. 2016 ，VOL. 24 ， 现代肿瘤医学 年 月 第 卷第 期 NO. 07 11·17 · 白蛋白结合型紫杉醇联合贝伐珠单抗治疗复发性卵巢癌的临床分析 ， ， ， ， 陈 杰 陈春婷 关 慧 董丽娜 刘睿敏 Albumin type combined with paclitaxel plus beacizumab bead sheet resistance for the treatment of recurrent ovarian cancer Chen Jie ，Chen Chunting ，Guan Hui ，Dong Li＇na ，Liu Ｒuimin Department of Gynecology ，The Third Affiliated Hospital of Harbin Medical University，Heilongjiang Harbin 150081，China． 【Abstract 】 Objective :To study the curative effect of type albumin in combination with paclitaxel plus beacizumab bead sheet resistance in the treatment of recurrent ovarian cancer adverse reaction and survival conditions． Methods : We used type albumin in combination with paclitaxel plus beacizumab bead sheet resistance to treatment of 78 cases of recurrent ovarian cancer． 1st day type albumin in combination with paclitaxel 260mg /m2 ，beacizumab bead sheet re- sistance to 15mg /m2 ，21d for a cycle． Ｒesults :All 78 patients can be evaluated curative effect ，no complete remission cases，partial in 9 cases ，stable in 42 cases ，27 cases ，effective rate was 11． 5% (9 /78) ，the clinical benefit rate was 65． 4% (51 /78)． The main adverse reactions were bone marrow suppression，gastrointestinal tract reaction ，fatigue ， hair loss ，peripheral nerve toxicity ，skin rashes ，high blood pressure ，muscle aches． More adverse reactions were level I and level II ，the side effects can be tolerated ，no treatment － related death． Conclusion :The combination of albumin type paclitaxel plus beacizumab bead sheet resistance in the treatment of recurrent ovarian cancer can obtain better curative effect ，adver